Califf cautions against lowering FDA standards; Editas outlines $1B milestone package
→ Ex-FDA Commissioner Robert Califf is back at Duke. And he has some advice for the Trump administration as it follows through on plans to reorganize the agency and cut review times. “Shortening and expediting is a great idea, but it needs to be done without lowering the standards,” Califf told Duke’s The Chronicle. In the student newspaper, Califf pointed out that more than 90 percent of drugs entering clinical trials currently do not make it to the market. If regulations are loosened to approve those, he said “a lot of people are going to get hurt or end up taking ineffective drugs.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.